NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
Similar Posts
The Crawford Resignation Mystery
The Crawford Resignation Mystery Sat, 24 Sep 2005 Merrill Goozner of Center for Science in the Public Interest provides insight into what may lie behind the sudden resignation of FDA Commissioner, Lester Crawford. Goozner surggests, “One possible clue to the administration’s thinking comes from the appointment of Andrew von Eschenbach,…
Psychiatry’s “Desperate Cures?” Electric Switches for Depression?
An OpEd in The New York Times (below) is trumpeting psychiatry’s latest “cure” for depression: it requires surgical implantation of electrodes in the brain, continued “maintenance” with powerful psychotropic drugs, and it costs $40,000.
Infomail Archive 2004
Infomail 2004 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 31: FDA to review “missing” drug company documents Dec 30: Family of Woman Killed by AIDS Drug Test Sues Doctors, Manufacturer Dec 30: Doctors, Too, Ask: Is This Drug Right? Dec 29: Bill would shield…
Office of Special Counsel Affirms whistleblower protection for ALL gov employees
Good news! The Associated Press reports that the U.S. Merit Systems Proteciton Board ruled in favor of extending whistleblower protection to ALL government doctors, including those hired under Title 42.
Antibiotic Ketek Trial in Children
One day following a rport in The New York Times, Sanifo-Aventis, manufacturer of Ketek, suspended the trial in children. The FDA has not announced any action.
2/3 Institute of Medicine AIDS research panel have Conflicts of Interst – Assoc Press
2/3 Institute of Medicine AIDS research panel have Conflicts of Interst – Assoc Press Thu, 17 Mar 2005 On Feb 25, the New York Times reported that 10 of 32 FDA panelists determining whether to recommend that COX 2 painkillers should allowed to be marketed despite the documented increased risk…